Milestone - SR1375'S Phase II Clinical Trial Approved by th
On December 13, 2022，Shanghai SIMR Biotechnology Co., Ltd announced that, the candidate drug SR1375 with a new mechanism of action for the treatment of acute inflammation solely developed by the compa...
